Pharmaceutical Technology22 小时
QRL-101 by QurAlis for Epilepsy: Likelihood of Approval
QRL-101 is under clinical development by QurAlis and currently in Phase I for Epilepsy. According to GlobalData, Phase I drugs for Epilepsy have an 84% phase transition success rate (PTSR) indication ...
Pharmaceutical Technology22 小时
NBI-1117568 by Neurocrine Biosciences for Schizophrenia: Likelihood of Approval
NBI-1117568 is under clinical development by Neurocrine Biosciences and currently in Phase II for Schizophrenia.